A business in context

GRI research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-23 · 8022 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. DEF 14A · Proxy statement

    Report date 2026-11-04 · 0001824293-26-000060

  2. 8-K · Current report

    Report date 2026-09-08 · 0001824293-26-000057 · Items 7.01,8.01,9.01

  3. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001824293-26-000055

  4. 8-K · Current report

    Report date 2026-06-18 · 0001824293-26-000050 · Items 8.01,9.01

  5. 8-K · Current report

    Report date 2026-05-14 · 0001824293-26-000046 · Items 2.02,8.01,9.01

  6. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001824293-26-000044

  7. 8-K · Current report

    Report date 2026-02-04 · 0001824293-26-000040 · Items 2.02,9.01

  8. 10-K · Annual report

    Report date 2025-12-31 · 0001824293-26-000033

  9. 8-K · Current report

    Report date 2026-01-29 · 0001824293-26-000030 · Items 1.01,9.01

  10. 8-K · Current report

    Report date 2026-01-28 · 0001824293-26-000017 · Items 8.01,9.01

  11. 8-K · Current report

    Report date 2026-01-21 · 0001824293-26-000014 · Items 3.03,5.03,8.01,9.01

  12. 8-K · Current report

    Report date 2026-01-15 · 0001824293-26-000011 · Items 3.01

  13. 8-K · Current report

    Report date 2026-01-15 · 0001824293-26-000009 · Items 5.07,8.01

  14. 8-K · Current report

    Report date 2026-01-09 · 0001824293-26-000006 · Items 8.01,9.01

  15. 8-K · Current report

    Report date 2026-01-08 · 0001824293-26-000002 · Items 8.01,9.01

  16. DEF 14A · Proxy statement

    Report date 2026-01-15 · 0001824293-25-000173

  17. 8-K · Current report

    Report date 2025-12-12 · 0001628280-25-056751 · Items 8.01,9.01

  18. 8-K · Current report

    Report date 2025-12-11 · 0001628280-25-056659 · Items 1.01,9.01

  19. 8-K · Current report

    Report date 2025-12-10 · 0001824293-25-000167 · Items 8.01,9.01

  20. 8-K · Current report

    Report date 2025-12-08 · 0001824293-25-000160 · Items 8.01

  21. 8-K · Current report

    Report date 2025-11-26 · 0001824293-25-000155 · Items 3.01

  22. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001824293-25-000151

  23. 4 · Ownership change

    Report date 2025-09-18 · 0001971423-25-000003

  24. 4 · Ownership change

    Report date 2025-09-18 · 0001971132-25-000006

  25. 4 · Ownership change

    Report date 2025-09-18 · 0001844060-25-000003

  26. 4 · Ownership change

    Report date 2025-09-18 · 0001822557-25-000005

  27. 4 · Ownership change

    Report date 2025-09-18 · 0001698966-25-000004

  28. 4 · Ownership change

    Report date 2025-09-18 · 0001602459-25-000004

  29. 4 · Ownership change

    Report date 2025-09-18 · 0001398278-25-000004

  30. 4 · Ownership change

    Report date 2025-08-26 · 0001824293-25-000144

  31. 8-K · Current report

    Report date 2025-08-20 · 0001824293-25-000126 · Items 7.01,9.01

  32. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001824293-25-000106

  33. 8-K · Current report

    Report date 2025-08-13 · 0001824293-25-000096 · Items 5.02,5.07,9.01

  34. 8-K · Current report

    Report date 2025-07-31 · 0001824293-25-000094 · Items 8.01,9.01

  35. DEF 14A · Proxy statement

    Report date 2025-08-13 · 0001824293-25-000089

  36. 8-K · Current report

    Report date 2025-06-26 · 0001824293-25-000082 · Items 7.01,9.01

  37. 8-K · Current report

    Report date 2025-05-23 · 0001824293-25-000079 · Items 8.01,9.01

  38. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001824293-25-000073

  39. 8-K · Current report

    Report date 2025-05-15 · 0001824293-25-000072 · Items 2.02,9.01

  40. 8-K · Current report

    Report date 2025-05-05 · 0001824293-25-000063 · Items 8.01,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-23 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 0 transaction rows0AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

0 matching transaction rows.

No matching transaction rows in the covered quarter. This does not establish that no insider transactions occurred.

Identity & relationships

Wikidata structured data · retrieved 2026-10-23 · 1658 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001824293GRI Bio, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-23 · 1197 checked identities; 0 unavailable records

Search names and former names
  • Vallon Pharmaceuticals, Inc. · former SEC name · 2020-09-11 to 2023-04-21

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2021-12-31$0$0
2020-12-31$100.0K$130.2K

Bureau of Labor Statistics · retrieved 2026-10-23 · 9 selected series; gaps remain missing

Explore the CPI history ↗